Our results, however, disagree with the observational analysis of Patorno et al.,21 who reported no significant difference in the risk of a composite CV outcome (MI, unstable angina, stroke, or coronary revascularization) between users of GLP-1 RAs and DPP-4 inhibitors. Here, GLP1R is linked to angina pectoris.